Rohit N. Kulkarni

Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data

D. Ward, R. Ebrahimi, A. Cheng, 2014, HIV clinical trials.

1205 SVR-12 AMONG G1/4 TREATMENT-NAIVE PATIENTS RECEIVING MERICITABINE IN COMBINATION WITH PEG-IFNa-2A/RBV: INTERIM ANALYSIS FROM THE JUMP-C STUDY

C. Cooper, P. Pockros, D. Jensen, 2012 .

Phase 1 clinical trial for intravenous administration of mesenchymal stem cells derived from umbilical cord and placenta in patients with moderate COVID-19 virus pneumonia: results of stage 1 of the study.

Mazhar I. Khan, A. Sharma, P. Badhe, 2022, American journal of stem cells.

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.

Stuart K. Roberts, R. Elston, P. Angus, 2012, Gastroenterology.

JUMP‐C: A randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients

C. Cooper, P. Pockros, D. Jensen, 2013, Hepatology.

Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders

R. Petric, E. Gane, D. Larrey, 2013, Antimicrobial Agents and Chemotherapy.

Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.

C. Bernaards, Patrick F. Smith, Ya-Chi Chen, 2014, British journal of clinical pharmacology.

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

P. N. Morcos, Patrick F. Smith, Linda Chang, 2013, European Journal of Clinical Pharmacology.